International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 3 , Pages 679-684 , 1 March 2010

Clinicopathologic Significance of Excision Repair Cross-Complementation 1 Expression in Patients Treated With Breast-Conserving Surgery and Radiation Therapy

  • Sharad Goyal, M.D.

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ
    • Corresponding Author InformationReprint requests to: Sharad Goyal, M.D., Department of Radiation Oncology, The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903. Tel: (732) 253-3929; Fax: (732) 235-7493
    • ,
  • Rahul R. Parikh, M.D.

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ
    • ,
  • Camille Green, M.D.

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ
    • ,
  • Devora Schiff, B.S.

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ
    • ,
  • Meena S. Moran, M.D.

      Affiliations

    • Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT
    • ,
  • Qifeng Yang, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ
    • Department of Breast Surgery, Qilu Hospital/Shandong University, People's Republic of China
    • ,
  • Bruce G. Haffty, M.D.

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ

Received 12 December 2008 ,Revised 18 February 2009 ,Accepted 19 February 2009.

References 

  1. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–1241
  2. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567–575
  3. Luini A, Gatti G, Zurrida S, et al. The evolution of the conservative approach to breast cancer. Breast. 2007;16:120–129
  4. Haffty BG, Carter D, Flynn SD, et al. Local recurrence versus new primary: Clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting. Int J Radiat Oncol Biol Phys. 1993;27:575–583
  5. Fisher B, Anderson S, Fisher ER, et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet. 1991;338:327–331
  6. Borger J, Kemperman H, Hart A, et al. Risk factors in breast-conservation therapy. J Clin Oncol. 1994;12:653–660
  7. Kurtz JM, Jacquemier J, Amalric R, et al. Risk factors for breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapy. Cancer. 1990;65:1867–1878
  8. Fourquet A, Campana F, Zafrani B, et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: A 25-year follow-up. Int J Radiat Oncol Biol Phys. 1989;17:719–725
  9. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418–8423
  10. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–10874
  11. Turner BC, Gumbs AA, Carter D, et al. Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation. Int J Radiat Oncol Biol Phys. 2000;47:1169–1176
  12. Turner BC, Gumbs AA, Carbone CJ, et al. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy. Cancer. 2000;88:1091–1098
  13. Turner BC, Haffty BG, Narayanan L, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997;57:3079–3083
  14. Olaussen KA, Mountzios G, Soria JC. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med. 2007;13:284–289
  15. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–991
  16. Vilmar A, Sorensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature. Lung Cancer. 2008;In press
  17. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;366:2087–2106
  18. Recht A, Houlihan MJ. Conservative surgery without radiotherapy in the treatment of patients with early-stage invasive breast cancer. A review. Ann Surg. 1995;222:9–18
  19. Steffensen KD, Waldstrom M, Jeppesen U, et al. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer. 2008;18:702–710
  20. Jun HJ, Ahn MJ, Kim HS, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008;99:167–172
  21. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998;16:309–316
  22. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24:5652–5657
  23. Haffty BG, Fischer D, Fischer JJ. Regional nodal irradiation in the conservative treatment of breast cancer. Int J Radiat Oncol Biol Phys. 1990;19:859–865
  24. Pejavar S, Wilson LD, Haffty BG. Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS + RT). Int J Radiat Oncol Biol Phys. 2006;66:1320–1327
  25. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  26. Hwang IG, Ahn MJ, Park BB, et al. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer. 2008;113:1379–1386
  27. Kim MK, Cho KJ, Kwon GY, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer. 2008;44:54–60
  28. Fu JM, Zhou J, Xie JS, Li H. [Effect of neoadjuvant chemotherapy on ERCC1 gene expression in breast cancer]. Nan Fang Yi Ke Da Xue Xue Bao. 2008;28:603–605
  29. Sprong D, Janssen HL, Vens C, et al. Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. Int J Radiat Oncol Biol Phys. 2006;64:562–572
  30. Carles J, Monzo M, Amat M, et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006;66:1022–1030

 Conflict of interest: none.

PII: S0360-3016(09)00348-4

doi: 10.1016/j.ijrobp.2009.02.050

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 3 , Pages 679-684 , 1 March 2010

Article Tools

* Image Usage & Resolution